Encapsulation of Low Metronidazole Dose in Poly (D,L-lactide-co-glycolide) (PLGA) Nanoparticles Improves Giardia intestinalis Treatment
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The present study was designed to investigate the antigiardial efficacy of low metronidazole dose loaded-D.L-lactide-co-glycolide (LMD-PLGA) nanoparticles (NPs) and to compare it with the standard high dose of metronidazole either free (HMD) or loaded on PLGA (HMD-PLGA). Materials and Methods: PLGA NPs were prepared by single emulsification method, metronidazole (MTZ) was loaded in low and high doses. The nanoparticles were evaluated in vivo for mice model. The Giardia intestinalis infected mice were treated by LMD and HMD either free or PLGA NPs loaded, the parasitic load and ployclonal antigiardial serum antibodies (IgG and IgA) were recorded. Histopathological studies on intestinal and liver sections were applied. Results: MTZ-PLGA NPs was successfully prepared with 81.68% encapsulation efficiency and with an average particle size of approximately 228.00 ± 43.19 nm and -32.28 ± 0.07 mV Zeta potential. Experimentally, it was observed that Giardia intestinalis infected animals administered with LMD-PLGA had completely eliminated cyst shedding and trophozoite count compared with Giardia-infected mice. Further, it was found that animals belonging to LMD-PLGA group had significantly reduced levels of antigiardial IgA (0.99 ± 0.05) antibodies in serum compared with Giardia-infected. Histopathologyically, also animals belonging to LMD-PLGA treated group had intact mucosal epithelium lining, and normal villi with no detection of G. intestinalis trophozoites. In addition to the less toxic effect on the liver tissue compared to free HMD, HMD-PLGA and infected-untreated groups using Ishak grading system. Conclusion: Our study showed that PLGA nanoparticles could be atrial delivery systems for antigiardial drugs to improve their therapeutic efficacy and minimize their side effects that results from frequent dosing.
Abstract
Background: The present study was designed to investigate the antigiardial efficacy of low metronidazole dose loaded-D.L-lactide-co-glycolide (LMD-PLGA) nanoparticles (NPs) and to compare it with the standard high dose of metronidazole either free (HMD) or loaded on PLGA (HMD-PLGA). Materials and Methods: PLGA NPs were prepared by single emulsification method, metronidazole (MTZ) was loaded in low and high doses. The nanoparticles were evaluated in vivo for mice model. The Giardia intestinalis infected mice were treated by LMD and HMD either free or PLGA NPs loaded, the parasitic load and ployclonal antigiardial serum antibodies (IgG and IgA) were recorded. Histopathological studies on intestinal and liver sections were applied. Results: MTZ-PLGA NPs was successfully prepared with 81.68% encapsulation efficiency and with an average particle size of approximately 228.00 ± 43.19 nm and -32.28 ± 0.07 mV Zeta potential. Experimentally, it was observed that Giardia intestinalis infected animals administered with LMD-PLGA had completely eliminated cyst shedding and trophozoite count compared with Giardia-infected mice. Further, it was found that animals belonging to LMD-PLGA group had significantly reduced levels of antigiardial IgA (0.99 ± 0.05) antibodies in serum compared with Giardia-infected. Histopathologyically, also animals belonging to LMD-PLGA treated group had intact mucosal epithelium lining, and normal villi with no detection of G. intestinalis trophozoites. In addition to the less toxic effect on the liver tissue compared to free HMD, HMD-PLGA and infected-untreated groups using Ishak grading system. Conclusion: Our study showed that PLGA nanoparticles could be atrial delivery systems for antigiardial drugs to improve their therapeutic efficacy and minimize their side effects that results from frequent dosing.
참고문헌 (39)
- Palomo-Ligas L, "Identification of a novel potassium channel (GiK) as a potential drug target in Giardia lamblia:Computational descriptions of binding sites", Peer J, 7, pp.e6430~ (2019)
- Tejman-Yarden N, "New approaches to the treatment of giardiasis", Curr Opin Infect Dis, 24, pp.451~456 (2011)
- Escobedo AA, "Treatment of refractory paediatric giardiasis using secnidazole plus albendazole : a case series", Infez Med, 26, pp.379~384 (2018)
- Ansell BR, "Drug resistance in Giardia duodenalis", Biotechnol Adv, 33, pp.888~901 (2015)
- Xu W, "Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs", J Drug Deliv, 2013, pp.340315~ (2013)
- Hillaireau H, "Nanocarriers' entry into the cell : relevance to drug delivery", Cell Mol Life Sci, 66, pp.2873~2896 (2009)
- Hans ML, "Biodegradable nanoparticles for drug delivery and targeting", Curr Opin Solid State Mater Sci, 6, pp.319~327 (2002)
- Mahapatro A, "Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines", J Nanobiotechnology, 9, pp.55~ (2011)
- Dinarvand R, "Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents", Int J Nanomedicine, 6, pp.877~895 (2011)
- Mahboob T, "Preparation of Poly(DL-Lactideco-Glycolide)nanoparticles encapsulated with periglaucine A and betulinic acid for in vitro antiAcanthamoeba and cytotoxicity activities", Pathogens, 7, pp.62~ (2018)
- Aly EM, "Efficacy of combination therapy(metronidazole and", or artemether)in experimental giardiasis and its impact on nonenzymatic oxidative stress biomarkers, 2014, pp.7, 68~74
- Niwa T, "Preparation of biodegradable nanoparticles of water-soluble and insoluble drugs with D, L-lactide", glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior, 1993, pp.25, 89~98
- Walderich B, "A new method for isolation and differentiation of native Entamoeba histolytica and E. dispar cysts from fecal samples", Parasitol Res, 83, pp.719~721 (1997)
- Solaymani-Mohammadi S, "A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis", PLoS Negl Trop Dis, 4, pp.e682~ (2010)
- Blagg W, "A new concentration technic for the demonstration of protozoa and helminth eggs in feces", Am J Trop Med Hyg, 4, pp.23~28 (1955)
- Drury RAB, "Histopathological stains and their diagnostic uses", J Clin Pathol, 2, pp.841~ (1975)
- Ishak K, "Histological grading and staging of chronic hepatitis", J Hepatol, 22, pp.696~699 (1995)
- Vivancos V, "Giardiasis : characteristics, pathogenesis and new insights about treatment", Curr Top Med Chem, 18, pp.1287~1303 (2018)
- Walker S, "Small animal toxicology", Can Vet J, 55, pp.844~ (2014)
- National Toxicology Program, "NTP 12th report on carcinogens", Rep Carcinog, 12, pp.iii~499 (2011)
- Lemée V, "Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France", J Antimicrob Chemother, 46, pp.819~821 (2000)
- Bezagio RC, "Synergistic effects of fenbendazole and metronidazole against Giardia muris in Swiss mice naturally infected", Parasitol Res, 116, pp.939~944 (2017)
- Singh M, "Development of sodium alginate coated nanoparticles of metronidazole for the treatment of periodontitis", Int J App Pharm, 11, pp.105~110 (2019)
- Kobayashi H, "Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?", Theranostics, 4, pp.81~89 (2014)
- Lu B, "Chitosan-modified PLGA nanoparticles for control-released drug delivery", Polymers(Basel), 11, pp.304~ (2019)
- Fahmy ZH, "The effect of medium chain saturated fatty acid(monolaurin)on levels of the cytokines on experimental animal in Entamoeba histolytica and Giardia lamblia infection", Afr J Pharm Pharmacol, 8, pp.106~114 (2014)
- Pereira M, "Prevalence and associated risk factors for Giardia lamblia infection among children hospitalized for diarrhea in Goiânia, Goiás State, Brazil", Rev Inst Med Trop São Paulo, 49, pp.139~145 (2007)
- Barzegar-Jalali M, "Comparison of physicochemical characteristics and drug release of diclofenac sodium–eudragit® RS100nanoparticles and solid dispersions", Powder Technol, 219, pp.211~216 (2012)
- Aina A, "Monitoring model drug microencapsulation in PLGA scaffolds using X-ray powder diffraction", Saudi Pharm J, 24, pp.227~231 (2016)
- Bendesky A, "Is metronidazole carcinogenic?", Mutat Res, 511, pp.133~144 (2002)
- Grace EO, "A histological studies of the ameliorative effect of turmeric(curcuma longa)on the liver of metronidazole-treated albino wistar rats", World J Pharm Sci, 4, pp.311~320 (2015)
- Jenkins MC, "Antibodies to the ventral disc protein δ-giardin prevent in vitro binding of Giardia lamblia trophozoites", J Parasitol, 95, pp.895~899 (2009)
- Sullivan PB, "Evaluation of specific serum anti-Giardia IgM antibody response in diagnosis of giardiasis in children", Trans R Soc Trop Med Hyg, 85, pp.748~749 (1991)
- Jiménez JC, "Antibody response in children infected with Giardia intestinalis before and after treatment with secnidazole", Am J Trop Med Hyg, 80, pp.11~15 (2009)
- Bajeva UK, "Humoral response in giardiasis", J Commun Dis, 15, pp.256~260 (1983)
- Hjøllo T, "Longitudinal cohort study of serum antibody responses towards Giardia lamblia variant-specific surface proteins in a non-endemic area", Exp Parasitol, 191, pp.66~72 (2018)
- Birkhead G, "Elevated levels of immunoglobulin A to Giardia lamblia during a waterborne outbreak of gastroenteritis", J Clin Microbiol, 27, pp.1707~1710 (1989)
- Shukla G, "Protective potential of L. acidophilus in murine giardiasis", Cent Eur J Med, 5, pp.456~463 (2010)
- Priest JW, "Multiplex assay detection of immunoglobulin G antibodies that recognize Giardia intestinalis and Cryptosporidium parvum antigens", Clin Vaccine Immunol, 17, pp.1695~1707 (2010)
